A pilot, prospective evaluation of a direct thrombin inhibitor, bivalirudin (Angiomax), in patients undergoing lower extremity bypass
To access this article, please choose from the options below
Supported by The Medicines Company.
Competition of interest: none.
The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a competition of interest.
PII: S0741-5214(10)00661-0
doi:10.1016/j.jvs.2010.02.276
© 2010 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.
